Corcept Therapeutics Inc. (CORT) is a commercial-stage company discovering and developing drugs to modulate the effects of the stress hormone cortisol, for the treatment of severe metabolic, oncologic and psychiatric disorders. Corcept has an approved drug, Korlym (mifepristone), for Cushing’s syndrome. However, a new drug, relacorilant, is being trialed in this indication, which is better than Korlym as well as competing drugs from the pipelines of a few other companies. However, these other competing drugs will hit the market sooner than relacorilant. That is the story we will investigate here using our IOMachine